PTC Therapeutics Canada ULC
Call for patient/clinician input open:
Call for patient/clinician input closed:
Manufacturer Requested Reimbursement Criteria1:
For the treatment of dystrophinopathy resulting from a nonsense mutation in the dystrophin gene.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.